Apellis Pharmaceuticals, Inc.
APLSDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001492422
Apellis Pharmaceuticals, Inc. was delisted in 2026; its insiders filed their last Form 4 on May 14, 2026; 324 institutions reported holding it in 13F filings for Q1 2026, worth $5.56B in total; Soros Fund Management was the only superinvestor holding it.
13F holders, Q1 2026
Institutional positions in Apellis Pharmaceuticals, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
APLS is no longer listed, so this page shows Q1 2026. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 324
- +49 vs. Q4 2025
- Shares held
- 140.4M
- +25.8M (+22.6%) vs. Q4 2025
- Total value
- $5.56B
- +$2.69B (+93.5%) vs. Q4 2025
- New holders
- 127
- 91 more added
- Sold out
- 78
- 72 more reduced
5 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting APLS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $10.2K |
| Q1 2026 | 324 | $5.56B |
| Q4 2025 | 280 | $3.17B |
| Q3 2025 | 273 | $2.77B |
| Q2 2025 | 247 | $2.29B |
| Q1 2025 | 255 | $2.80B |
| Q4 2024 | 260 | $4.05B |
| Q3 2024 | 265 | $3.52B |
| Q2 2024 | 263 | $4.56B |
| Q1 2024 | 302 | $6.97B |
| Q4 2023 | 284 | $7.16B |
| Q3 2023 | 256 | $4.34B |
| Q2 2023 | 317 | $9.81B |
| Q1 2023 | 282 | $7.49B |
| Q4 2022 | 244 | $5.26B |
| Q3 2022 | 250 | $6.67B |
| Q2 2022 | 212 | $4.15B |
| Q1 2022 | 212 | $4.62B |
| Q4 2021 | 187 | $3.91B |
| Q3 2021 | 181 | $2.29B |
| Q2 2021 | 205 | $4.13B |
| Q1 2021 | 175 | $2.80B |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Apellis Pharmaceuticals, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Rothschild Investment LLC | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| Transamerica Financial Advisors, Inc. | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |
| Norges Bank | – | – | – | – | Not filed |
| CIBC Private Wealth Group, LLC | – | – | – | – | Not filed |
| Comerica Bank | – | – | – | – | Not filed |
| Global Retirement Partners, LLC | – | – | – | – | Not filed |